Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis

Summary

Immune mediated heparin induced thrombocytopenia (HIT) is a prothrombotic adverse effect of heparin. However, only a subgroup of patients with HIT develops thromboembolic complications. We aimed to identify risk factors for developing HITassociated thrombosis. We analyzed a registry of patients with clinical suspicion of HIT who tested positive using a sensitive functional assay. Patient information was obtained by a standardized questionnaire. By multivariate analysis the association of age, gender, type of patient population, and magnitude of the platelet count decline with the frequency, type (venous or arterial), and temporal pattern of thrombotic events was assessed. In 408 HIT patients we observed predominance of venous thrombosis (2.4:1), with 40% of patients developing a pulmonary embolism. However, in the subgroup of post-cardiovascular surgery patients there was predominance of arterial thrombosis (1:8.5). The type of arterial thrombosis (limb artery thrombosis > thrombotic stroke > myocardial infarction) was the converse of that observed with typical atherothrombotic clots in non-HIT populations. In 59.8% of patients HIT-related thrombosis manifested either on the same day a platelet count decrease >50% was documented (26.3%) or before the decrease in platelet counts (33.5%).The most important risk factors for thrombosis were orthopedic/trauma surgery and the magnitude of platelet count decrease. HIT-associated thrombosis occurs in a considerable proportion of patients before platelet counts decrease by more than 50%.

Keywords

Heparin - heparin-induced thrombocytopenia - platelets - thrombosis

^* The sponsors of the study had no role in study design, data analysis or interpretation, or the writing of the report. None of the authors declare a conflict of interest or financial interest.

• References

• 1 Warkentin TE, Chong BH, Greinacher A. Heparininduced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79: 1-7.
• 2 Li ZQ, Liu W, Park KS. et al. Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. Blood 2002; 99: 1230-6.
• 3 Warkentin TE, Hayward CP, Boshkov LK. et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994; 84: 3691-9.
• 4 Greinacher A, Eichler P, Lubenow N. et al. Heparininduced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000; 96: 846-51.
• 5 Warkentin TE, Sheppard JA, Horsewood P. et al. Impact of the patient population on the risk for heparininduced thrombocytopenia. Blood 2000; 96: 1703-8.
• 6 Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Heparin-induced thrombocytopenia. 3nd ed.. Marcel Dekker.; 2004: 53-106.
• 7 Lee DH, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: Heparin-induced thrombocytopenia. 3rd ed.. Marcel Dekker; 2004: 107-48.
• 8 Eichler P, Budde U, Haas S. et al. First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb Haemost 1999; 81: 625-9.
• 9 Farner B, Eichler P, Kroll H. et al. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001; 85: 950-7.
• 10 Warkentin TE, Kelton JG. A 14-year study of heparininduced thrombocytopenia. Am J Med 1996; 101: 502-7.
• 11 Warkentin TE, Roberts RS, Hirsh J. et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Archives of Internal Medicine 2003; 163: 2518-24.
• 12 Boshkov LK, Warkentin TE, Hayward CP. et al. Heparin- induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 1993; 84: 322-28.
• 13 Fabris F, Luzzatto G, Soini B. et al. Risk factors for thrombosis in patients with immune mediated heparininduced thrombocytopenia. Journal of Internal Medicine 2002; 252: 149-54.
• 14 Wallis DE, Lewis BE, Walenga JM. Failure of current strategies in the prevention of thrombosis in patients with heparin-induced thrombocytopenia: a clinician’s perspective. Semin Thromb Hemost 1999; 25 (Suppl. 01) 3-7.
• 15 Tardy B, Tardy-Poncet B, Fournel P. et al. Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia. Thromb Haemost 1999; 82: 1199-200.
• 16 Lubenow N, Eichler P, Lietz T. et al. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of three prospective studies. Blood 2004; 104: 3072-7.
• 17 Hach-Wunderle V, Kainer K, Krug B. et al. Heparinassociated thrombosis despite normal platelet counts. Lancet 1994; 344: 469-70.
• 18 Warkentin TE, Levine MN, Hirsh J. et al. Heparininduced thrombocytopenia in patients treated with lowmolecular- weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
• 19 Geerts WH, Pineo GF, Heit JA. et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S-400S.